# The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers

> **NCT04019652** · PHASE1 · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 55 (actual)

## Conditions studied

- Hypertension
- Mineralocorticoid Receptor Antagonist

## Interventions

- **DRUG:** CS-3150
- **DRUG:** Moxifloxacin
- **DRUG:** Placebo matching moxifloxacin tablet
- **DRUG:** Placebo matching CS-3150

## Key facts

- **NCT ID:** NCT04019652
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-19
- **Primary completion:** 2015-12-23
- **Final completion:** 2015-12-23
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2019-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04019652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04019652, "The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04019652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*